Literature DB >> 34113990

"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.

David C Nguyen1,2, Khalid M Dousa3, Sebastian G Kurz4, Sheldon T Brown5,6, George Drusano7, Steven M Holland8, Barry N Kreiswirth9, W Henry Boom1,10, Charles L Daley11, Robert A Bonomo12,13,14.   

Abstract

Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in vitro but are not widely employed in practice. A recent study shows that a combination of imipenem and ceftaroline significantly lowers the minimum inhibitory concentration of clinical isolates, despite both drugs targeting the same peptidoglycan synthesis enzymes. The underlying mechanism of this effect provides a basis for further investigations of dual β-lactam combinations in the treatment of M. abscessus subsp. abscessus, eventually leading to a clinical trial. Furthermore, dual β-lactam strategies may be explored for other difficult mycobacterial infections.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Mycobacterium abscessuszzm321990 ; L,D-transpeptidase; ceftaroline; dual beta-lactam; imipenem

Mesh:

Substances:

Year:  2021        PMID: 34113990      PMCID: PMC8677594          DOI: 10.1093/cid/ciab535

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  37 in total

Review 1.  Drug-Resistant Tuberculosis: A Glance at Progress and Global Challenges.

Authors:  Khalid M Dousa; Sebastian G Kurz; Charles M Bark; Robert A Bonomo; Jennifer J Furin
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

3.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Imipenem for treatment of tuberculosis in mice and humans.

Authors:  Henry F Chambers; Joan Turner; Gisela F Schecter; Masae Kawamura; Philip C Hopewell
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.

Authors:  Enrico Tortoli; Thomas A Kohl; Barbara A Brown-Elliott; Alberto Trovato; Sylvia Cardoso Leão; Maria Jesus Garcia; Sruthi Vasireddy; Christine Y Turenne; David E Griffith; Julie V Philley; Rossella Baldan; Silvia Campana; Lisa Cariani; Carla Colombo; Giovanni Taccetti; Antonio Teri; Stefan Niemann; Richard J Wallace; Daniela M Cirillo
Journal:  Int J Syst Evol Microbiol       Date:  2016-08-04       Impact factor: 2.747

6.  The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation.

Authors:  Marie Lavollay; Michel Arthur; Martine Fourgeaud; Lionel Dubost; Arul Marie; Nicolas Veziris; Didier Blanot; Laurent Gutmann; Jean-Luc Mainardi
Journal:  J Bacteriol       Date:  2008-04-11       Impact factor: 3.490

7.  Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.

Authors:  J L Mainardi; L Gutmann; J F Acar; F W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.

Authors:  Pankaj Kumar; Varsha Chauhan; José Rogério A Silva; Jerônimo Lameira; Felipe B d'Andrea; Shao-Gang Li; Stephan L Ginell; Joel S Freundlich; Cláudio Nahum Alves; Scott Bailey; Keira A Cohen; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

9.  The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model.

Authors:  Michal Meir; Pablo Bifani; Daniel Barkan
Journal:  Antimicrob Resist Infect Control       Date:  2018-12-13       Impact factor: 4.887

10.  Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.

Authors:  R Pandey; L Chen; C Manca; S Jenkins; L Glaser; C Vinnard; G Stone; J Lee; B Mathema; E L Nuermberger; R A Bonomo; B N Kreiswirth
Journal:  mBio       Date:  2019-02-12       Impact factor: 7.786

View more
  3 in total

1.  CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam Susceptibility.

Authors:  Natalia Kurepina; Liang Chen; Kaelea Composto; Dalin Rifat; Eric L Nuermberger; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

2.  Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Dereje A Negatu; Matthew D Zimmerman; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2022-09-01       Impact factor: 5.938

Review 3.  Mycobacterium abscessus: It's Complex.

Authors:  Hazem F M Abdelaal; Edward D Chan; Lisa Young; Susan L Baldwin; Rhea N Coler
Journal:  Microorganisms       Date:  2022-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.